Impact of in vivo fatty acid oxidation blockade on glucose turnover and muscle glucose metabolism during low-dose AICAR infusion

American Journal of Physiology - Endocrinology and Metabolism

Volumn 291, Issue 5, 2006, Pages

  Christopher, Michael ^a,b   Rantzau, Christian ^a,b   Chen, Zhi Ping ^a   Snow, Rodney ^c   Kemp, Bruce ^a   Alford, Frank P ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c DEAKIN UNIVERSITY   (Australia)

Author keywords

5 aminoimidazole 4 carboxamide 1 D ribofuranoside; 5 aminoimidazole 4 carboxamide 1 D ribosyl monophosphate; Acetyl coenzyme A carboxylase; Dogs; Muscle biopsy; Phosphorylation; Skeletal muscle

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ACETYL COENZYME A CARBOXYLASE; FATTY ACID; GLUCOSE; GLUCOSE 6 PHOSPHATE; GLYCOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DOG; DRUG EFFECT; FATTY ACID OXIDATION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; MALE; MUSCLE BIOPSY; MUSCLE METABOLISM; NONHUMAN; PRIORITY JOURNAL; SKELETAL MUSCLE;

ACETYL-COA CARBOXYLASE; ADENOSINE MONOPHOSPHATE; ADENOSINE TRIPHOSPHATE; AMINOIMIDAZOLE CARBOXAMIDE; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DOGS; EPOXY COMPOUNDS; FATTY ACIDS; GLUCAGON; GLUCOSE; GLUCOSEPHOSPHATE DEHYDROGENASE; GLYCOGEN; HYPOGLYCEMIC AGENTS; INSULIN; LACTIC ACID; MALE; MULTIENZYME COMPLEXES; MUSCLE, SKELETAL; OXIDATION-REDUCTION; PROPIONATES; PROTEIN-SERINE-THREONINE KINASES; RIBONUCLEOTIDES; SERINE;

EID: 33751177787     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00518.2005     Document Type: Article

References (67)

1. Aiston S, Hampson L, Gomez-Foix AM, Guinovart JJ, and Agius L. Hepatic glycogen synthesis is highly sensitive to phosphorylase activity: evidence from metabolic control analysis. J Biol Chem 276: 23858-23866, 2001.
2. Akkan AG and Malaisse WJ. Insulinotropic action of AICA riboside. Insulin release by isolated islets and the perfused pancreas. Diabetes Res 25: 13-23, 1994.
3. Al-Khalili L, Krook A, Zierath JR, and Cartee GD. Prior serum and AICAR-induced AMPK activation in primary human myocytes does not lead to subsequent increase in insulin-stimulated glucose uptake. Am J Physiol Endocrinol Metab 287: E553-E557, 2004.
4. Bailey JW, Jensen MD, and Miles JM. Effects of intravenous methylpalmoxirate on the turnover and oxidation of fatty acids in conscious dogs. Metab Clin Exp 40: 428-431, 1991.
5. Bergeron R, Previs SF, Cline GW, Perret P, Russell RR, Young LH, and Shulman GI. Effect of 5-amino-imidazole-4-carboxamide-β-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. Diabetes 50: 1076-1082, 2001.
6. Bergeron R, Russell RR, Young LH, Ren JM, Marucci M, Lee A, and Shulman G. Effect of AMPK activation on muscle glucose in conscious rats. Am J Physiol Endocrinol Metab 276: E938-E944, 1999.
7. Beyer A, Kitzerow A, Crute B, Kemp BE, Witters LA, and Heilmeyer LMP. Muscle phosphorylase kinase is not a substrate of AMP-activated protein kinase. Biol Chem 381: 457-461, 2000.
8. Camacho RC, Lacy DB, James FD, Donahue EP, and Wasserman DH. 5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranoside renders glucose output by the liver of the dog insensitive to a pharmacological increment in insulin. Am J Physiol Endocrinol Metab 289: E1039-E1043, 2005.
9. Camacho RC, Pencek RR, Lacy DB, James FD, Donahue EP, and Wasserman DH. Portal venous 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside infusion overcomes hyperinsulinaemic suppression of endogenous glucose output. Diabetes 54: 373-382, 2005.
10. Carling D and Hardie DG. The substrate and sequence specificity of AMP-activated protein kinase. Phosphorylation of glycogen synthase and phosphorylase kinase. Biochim Biophys Acta 1012: 81-86, 1989.
11. Chen ZP, McConnell GK, Michell BJ, Snow RJ, Canny BJ, and Kemp BE. AMPK signaling in contracting skeletal muscle: acetyl-CoA carboxylase and NO synthase phosphorylation. Am J Physiol Endocrinol Metab 279: E1202-E1206, 2000.
12. Christopher MJ, Chen ZP, Rantzau C, Kemp BE, and Alford FP. Skeletal muscle basal AMP-activated protein kinase activity is chronically elevated in alloxan-diabetic dogs: impact of exercise. J Appl Physiol 95: 1523-1530, 2003.
13. Christopher MJ, Rantzau C, McConell G, Kemp BE, and Alford FP. Prevailing glycemia is critical to the regulation of glucose metabolism during exercise in poorly controlled alloxan-diabetic dogs. J Appl Physiol 98: 930-939, 2005.
14. Christopher MJ, Rantzau C, Ward GM, and Alford FP. Impact of variable glycemia and insulinemia on in vivo glycolysis and glucose storage in dogs. Am J Physiol Endocrinol Metab 266: E62-E71, 1994.
15. Christopher MJ, Rantzau C, Ward GM, and Alford FP. Hypoinsulinemia and hyperglycemia influences the in vivo partitioning of GE and SI. Am J Physiol Endocrinol Metab 268: E410-E414, 1995.
16. Christopher MJ, Sleeman MW, Alford FP, and Best JD. Contrasting action of short and long-term adrenaline infusion on dog skeletal muscle glucose metabolism. Diabetologia 35: 399-405, 1992.
17. Connolly CC, Steiner KE, Stevenson RW, Neal DW, Williams PE, Alberti KG, and Cherrington AD. Regulation of glucose metabolism by norepinephrine in conscious dogs. Am J Physiol Endocrinol Metab 261: E764-E772, 1991.
18. Corton JM, Gillespie JG, Hawkey SA, and Hardie DG. 5-Aminoimidazole-4- carboxamide ribonucleotide: a specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem 229: 558-565, 1995.
19. da Silva Xavier G, Leclerc I, Varadi A, Tsuboi T, Moule SK, and Rutter GA. Role for AMP-activated protein kinase in glucose-stimulated insulin secretion and preproinsulin gene expression. Biochem J 371: 761-774, 2003.
20. Del Prato S, Bonadonna RC, Bonora E, Gulli G, Solini A, Shank M, and DeFronzo RA. Characterisation of defects of insulin action in Type 2 diabetes mellitus. J Clin Invest 91: 484-494, 1993.
21. Eggstein M and Kuhlmann E. Triglyceride and glycerol determination after alkaline hydrolysis. In: Methods of Enzymatic Analysis, edited by Bergmeyer HN. New York: Academic, 1974, p. 1825-1831.
22. Ercan-Fang N, Gannon MC, Rath VL, Treadway JL, Taylor MR, and Nuttall FQ. Integrated effects of multiple modulations of human liver glycogen phosphorylase A. Am J Physiol Endocrinol Metab 283: E29-E37, 2002.
23. Henin N, Vincent MF, Gruber HE, and Van Den Berghe G. Inhibition of fatty acid and cholesterol synthesis by stimulation of AMP-activated protein kinase. FASEB J 9: 541-546, 1995.
24. Hother-Nielsen O, Henriksen JE, Holst JJ, and Beck-Nielsen H. Effects of insulin on glucose turnover rates in vivo: isotope dilution versus constant specific activity technique. Metabolism 45: 82-91, 1996.
25. Iglesias MA, Furler SM, Cooney GJ, Kraegen EW, and Ji-M Y. AMP-activated protein kinase activation by AICAR increases both muscle fatty acid and glucose uptake in white muscle of insulin-resistant rats in vivo. Diabetes 53: 1649-1654, 2004.
26. Inglesias MA, Ye JM, Frangioudakis G, Saha AK, Tomas E, Ruderman NB, Cooney GJ, and Kraegen EW. AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats. Diabetes 51: 2886-2894, 2002.
27. Jenkins AB, Storlien LH, Cooney GJ, Denyer GS, Caterson ID, and Kraegen EW. Effects of blockade of fatty acid oxidation on whole body and tissue-specific glucose metabolism in rats. Am J Physiol Endocrinol Metab 265: E592-E600, 1993.
28. Katz A, Raz I, Spenser MK, Rising R, and Mott DM. Hyperglycemia induces glucose accumulation in human skeletal muscle. Am J Physiol Regul Integr Comp Physiol 260: R698-R705, 1991.
29. Krebs HA. The Pasteur effect and the relations between respiration and fermentation. In: Essays in Biochemistry, edited by Campbell PN and Dickens F. London: Academic, 1972, p. 1-34.
30. Leclerc I, Woltersdorf WW, Da Silva-Xavier G, Rowe RL, Cross SE, Korbutt GS, Rajotte PV, Smith R, and Rutter GA. Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on glucose-stimulated insulin secretion. Am J Physiol Endocrinol Metab 286: E1023-E1031, 2004.
31. Lochhead PA, Salt IP, Walker KS, Hardie DG, and Sutherland C. 5-Aminoimidazole-4-carboxamide riboside mimics the effect of insulin on the expression of 2 key gluconeogenic genes PEPCK and glucose-6-phosphotase. Diabetes 49: 896-903, 2000.
32. Longnus SI, Wambolt RB, Parsons HL, Brownsey RW, and Allard MF. 5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) stimulates myocardial glycogenolysis by allosteric mechanisms. Am J Physiol Regul Integr Comp Physiol 284: R936-R944, 2003.
33. Martin IK, Weber KM, Boston RC, Alford FP, and Best JD. Effects of epinephrine infusion on determinants of intravenous glucose tolerance in dogs. Am J Physiol Endocrinol Metab 255: E668-E673, 1988.
34. Merrill GF, Kurth EJ, Hardie GD, and Winder WW. AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. Am J Physiol Endocrinol Metab 273: E1107-E1112, 1997.
35. Muoio DM, Seefeld K, Witters LA, and Coleman RA. AMP-activated kinase reciprocally regulates triacylglycerol synthesis and fatty acid oxidation in liver and muscle: evidence that sn-glycerol-3-phosphate acyltransferase is a novel target. Biochem J 388: 783-791, 1999.
36. Neilsen JN, Wojtaszewski JFP, Haller RG, Hardie DG, Kemp BE, Richter EA, and Vissing J. Roles of 5′-AMP-activated protein kinase in glycogen synthase activity and glucose utilisation: insights from patients with McArdle's Disease. J Physiol 541: 979-989, 2002.
37. Park SH, Gammon SR, Knippers JD, Paulsen SR, Rubink DS, and Winder WW. Phosphorylation-activity relationships of AMPK and acetyl-CoA carboxylase in muscle. J Appl Physiol 92: 2475-2482, 2002.
38. Pencek RR, Shearer J, Camacho RC, James FD, Lacy B, Fueger PT, Donahue EP, Snead W, and Wasserman DH. 5-Amino-imidazole-4-carboxamide-1-β-D- ribofuranoside causes acute hepatic insulin resistance in vivo. Diabetes 54: 335-360, 2005.
39. Pocai A, Obici S, Schwartz GJ, and Rossetti L. A brain-liver circuit regulates glucose homeostasis. Cell Metab 1: 53-61, 2005.
40. Randle PJ, Garland PB, Hales CN, and Newsholm EA. The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1: 785-789, 1963.
41. Rossetti L and Giaccari I. Relative contribution of glycogen synthesis and glycolysis to insulin-mediated glucose uptake. A dose response euglycaemic clamp study in normal and diabetic rats. J Clin Invest 85: 1785-1792, 1990.
42. Rutter GA, Da Silva Xavier G, and Leclerc I. Roles of 5′ AMP-activated protein kinase (AMPK) in mammalian glucose homeostasis. Biochem J 375: 1-16, 2003.
43. Salt IP, Johnson G, Ashcroft SJH, and Hardie DG. AMP-activated protein kinase is activated by low glucose in cell lines derived from pancreatic β cells, and may regulate insulin release. Biochem J 335: 533-539, 1998.
44. Schalin-Jantti C, Harkonen M, and Groop LC. Impaired activation of glycogen synthase in people with increased risk for developing NIDDM. Diabetes 41: 598-604, 1992.
45. Shang J and Lehrman MA. Activation of glycogen phosphorylase with 5-amino-imidazole-4-carboxamide riboside (AICAR): assessment of glycogen as a precursor of mannosyl residules in glycoconjugates. J Biol Chem 279: 12076-12080, 2004.
46. Sheu WHH, Hollenbeck CB, Wu MS, Jaspen JB, Chen YDI, and Reaven GM. Effect of different glucose infusion rate on quantification of hepatic glucose production. J Clin Endocrinol Metab 70: 1354-1360, 1990.
47. Shi ZQ, Giacca A, Yamatani K, Fisher S, Lickley LA, and Vranic M. Effects of subbasal insulin infusion on resting and exercise induced glucose turnover in depancreatized dogs. Am J Physiol Endocrinol Metab 264: E334-E341, 1993.
48. Sjogaard G, Adams RP, and Saltin B. Water and ion shifts in skeletal muscle of humans with intense dynamic knee extension. Am J Physiol Regul Integr Comp Physiol 248: R190-R196, 1985.
49. Sjogaard G and Saltin B. Extra and intracellular water spaces in muscle in man at rest and with dynamic exercise. Am J Physiol Regul Integr Comp Physiol 243: R271-R280, 1982.
50. Steele R, Wall SJ, Debodo RC, and Altszuler N. Measurement of size and turnover rate of body glucose pool by the isotope dilution method. Am J Physiol 187: 15-24, 1956.
51. Stephens TJ, Cann BJ, Snow RJ, and McConnell GK. 5′-Aminoimidazole- 4-carboxyamideribonucleoside activated glucose transport is not prevented by nitric oxide synthase inhibition in rat isolated skeletal muscle. Clin Exp Pharmacol Physiol 31: 419-423, 2004.
52. Stephens TJ, Chen ZP, Canny BJ, Michell BJ, Kemp BE, and McConell G. Progressive increase in human skeletal muscle AMPKα2 activity and acetyl-CoA carboxylase phosphorylation during exercise. Am J Physiol Endocrinol Metab 282: E688-E694, 2002.
53. Stevenson RW, Williams PE, and Cherrington AD. Role of glucagon suppression on gluconeogenesis during insulin treatment of conscious diabetic dog. Diabetologia 30: 782-790, 1987.
54. Tutwiler GF, Mohrbecker R, and Ho W. Methyl 2-tetradecylglycidate, an orally effective hypoglycaemic agent that inhibits long chain fatty acid oxidation selectively. Diabetes 28: 242-248, 1979.
55. Vaag A, Hother-Nielsen E, Skott P, Andersen P, Richter E, and Beck-Nielsen H. Effects of acute hyperglycaemia on glucose metabolism in skeletal muscles in IDMM patients. Diabetes 41: 174-182, 1992.
56. Vincent MF, Bontemps F, and Van den Berghe G. Inhibition of glycolysis by 5-amino-4 imidazolecarboxamide riboside in isolated rat hepatocytes. Biochem J 281: 267-272, 1992.
57. Vincent MF, Marangos PJ, Gruber HE, and Van den Berghe G. Inhibition by AICA riboside of gluconeogenesis in isolated rat hepatocytes. Diabetes 40: 1259-1266, 1991.
58. Winder WW and Hardie DG. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol Endocrinol Metab 277: E1-E10, 1999.
59. Wojtaszewski JF, Jorgensen SB, Hellsten Y, Hardie DG, and Richter EA. Glycogen-dependent effects of 5 aminoimidazole-4-carboxamide (AICA)-riboside on AMP-activated protein kinase and glycogen synthase activities in rat skeletal muscle. Diabetes 51: 284-292, 2002.
60. Woods A, Johnstone SR, Dickenson K, Leiper FC, Fryer LG, Neumann D, Schlattner U, Wallimann T, Carlson M, and Carling D. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol 13: 2004-2008, 2003.
61. Wynants J and Van Belle H. Single-run high performance liquid chromatography of nucleotides, nucleosides, and major purine bases and its application to different tissue extracts. Anal Biochem 144: 258-266, 1985.
62. Yamashita T, Eto K, Okazaki Y, Yamashita S, Yamauchi T, Sekine N, Nagai R, Noda RN, and Kadowaki T. Role of uncoupling protein-2 upregulation and triglyceride accumulation in impaired glucose-stimulated insulin secretion in a β-cell lipotoxicity model over expressing sterol regulatory element-binding protein-1c. Endocrinology 145: 3566-3577, 2004.
63. Yamatani K, Shi ZQ, Giacca A, Gupta R, Fisher S, Lickley LA, and Vranic M. Role of FFA-glucose cycle in glucoregulation during exercise in total absence of insulin. Am J Physiol Endocrinol Metab 263: E646-E653, 1992.
64. Young MA and Mullane KM. Progressive cardiac dysfunction with repeated pacing-induced ischemia: protection by AICA-riboside. Am J Physiol Heart Circ Physiol 261: H1570-H1577, 1991.
65. Young ME, Radda GD, and Leighton B. Activation of glycogen phosphorylase and glycogenolysis in rat skeletal muscle by AICAR: an activator of AMP-activated protein kinase. FEBS Lett 382: 43-47, 1996.
66. Zhang S and Kim KH. Glucose activation of acetyl CoA carboxylase in association with insulin secretion in a pancreatic beta-cell line. J Endocrinol 147: 33-41, 1995.
67. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, and Moller DE. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108: 1167-1174, 2001.